Form 8-K - Current report:
SEC Accession No. 0000950170-22-024145
Filing Date
2022-11-10
Accepted
2022-11-10 07:05:55
Documents
13
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aura-20221110.htm   iXBRL 8-K 66918
2 EX-99.1 aura-ex99_1.htm EX-99.1 334544
  Complete submission text file 0000950170-22-024145.txt   537192

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aura-20221110_pre.xml EX-101.PRE 9846
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aura-20221110.xsd EX-101.SCH 2478
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aura-20221110_lab.xml EX-101.LAB 13350
7 EXTRACTED XBRL INSTANCE DOCUMENT aura-20221110_htm.xml XML 4697
Mailing Address 80 GUEST STREET BOSTON MA 01235
Business Address 80 GUEST STREET BOSTON MA 01235 (617)500-8864
Aura Biosciences, Inc. (Filer) CIK: 0001501796 (see all company filings)

EIN.: 320271970 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40971 | Film No.: 221374885
SIC: 2836 Biological Products, (No Diagnostic Substances)